Current role
David Shook
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About David Shook
Nkarta, Inc. reported in an 8-K filed June 6, 2025 that David Shook resigned as Chief Medical Officer and Head of Research & Development, effective June 6, 2025. The proxy statement of Nkarta, Inc. reports total compensation of $1,900,182 for David Shook in fiscal 2024, including a base salary of $489,507. Disclosed compensation is on record for 2 fiscal years.
“On June 3, 2025, David Shook, M.D. notified Nkarta, Inc. (the "Company") of his decision to resign as Chief Medical Officer and Head of Research & Development of the Company to pursue other opportunities in the oncology space.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Lyell Immunopharma, Inc. (LYEL)
Proxy statement
CurrentStart not stated–present
-
Nkarta, Inc. (NKTX)
Proxy statement
Start not stated–2025-06-06
Company network
Recorded roles and call appearances connecting this person to public companies.
Nkarta, Inc.
NKTX
Leadership on record at Lyell Immunopharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Lynn Seely CEO, Board Member
- Cathy Friedman Chairman
- Lynn Seely, M.D. CFO
- Smital Shah CFO
- Stephen Hill COO
- Richard Goold CIO
- Mark Meltz General Counsel
- Veronica Sanchez Bulis Chief Accounting Officer
- Catherine Friedman Board Member
- Elizabeth Nabel Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Nkarta, Inc. (NKTX) | Chief Medical Officer, Head of Research and Development | $489,507 | $1,900,182 |
| 2023 | Nkarta, Inc. (NKTX) | Chief Medical Officer, Head of Research and Development | $459,800 | $1,510,050 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.